Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
A02 BC03
|
| gptkbp:available_on |
over-the-counter
prescription |
| gptkbp:brand |
gptkb:Prevacid
Zoton |
| gptkbp:casnumber |
103577-45-3
|
| gptkbp:category |
B
|
| gptkbp:chemical_formula |
C16 H19 N3 O2 S
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:composed_by |
reduction reaction
cyclization reaction oxidation reaction N-alkylation N-oxidation deprotection reaction hydrolysis reaction ring closure reaction sulfonamide reaction |
| gptkbp:contraindication |
severe liver disease
hypersensitivity to lansoprazole |
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:tablet
gptkb:capsule suspension |
| gptkbp:healthcare |
gptkb:1995
|
| https://www.w3.org/2000/01/rdf-schema#label |
lansoprazole
|
| gptkbp:interacts_with |
gptkb:methotrexate
gptkb:clopidogrel gptkb:digoxin gptkb:warfarin |
| gptkbp:lifespan |
1.5 hours
|
| gptkbp:long_term_use_risk |
gptkb:disease
stomach cancer bone fractures low magnesium levels |
| gptkbp:mechanism_of_action |
gptkb:gasoline
|
| gptkbp:metabolism |
liver
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea constipation |
| gptkbp:treatment |
gptkb:GERD
peptic ulcers erosive esophagitis |
| gptkbp:used_for |
treating gastroesophageal reflux disease (GERD)
treating peptic ulcers treating Zollinger-Ellison syndrome |
| gptkbp:bfsParent |
gptkb:Nexium
|
| gptkbp:bfsLayer |
5
|